Companies /Healthcare

Geron Corp

NASDAQ: GERN Biotechnology
$0.94
▼ $0.03 (−2.60%) today
Markets closed · 8:04pm ET

GERN at a Glance

Valuation
Market cap
$623.0M
Profitability
Revenue (TTM)
$217.5M
Profit margin
-22.0%
EPS (TTM)
$-0.08
Price
52-week range
$1 – $2
Street target
$3.50

Headquartered in Foster City, CA Fiscal year ends December NASDAQ: GERN geron.com

About Geron

Geron Corporation is a commercial-stage biopharmaceutical company focused on hematology and blood cancers, built on expertise in telomerase biology.

Its sole marketed medicine is RYTELO (imetelstat), a first-in-class oligonucleotide telomerase inhibitor. RYTELO is approved in the U.S. for adults with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents. It is approved in the European Union for transfusion-dependent anemia in very low, low or intermediate risk non-del 5q MDS. Treatment is given as a two-hour intravenous infusion every four weeks.

Revenue comes almost entirely from U.S. net product sales of RYTELO through about 1,700 ordering accounts, with community practices driving demand growth. A small amount of royalty income is also recorded. Geron has begun a gated commercial launch in targeted European markets, with availability expected in Germany by end of 2026 and in France in 2027.

After discontinuing the Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, the company is concentrated on LR-MDS. Ongoing activity includes investigator-sponsored and real-world evidence studies on mechanism, combinations, sequencing and earlier-line use. Geron is funded by cash and marketable securities, product revenue, and debt and synthetic royalty financing arrangements. Updated

GERN Coverage

6:55am ET
Investing

The 6 Most Shorted Nasdaq Stocks

Judging by the most shorted stocks traded on the Nasdaq between the September 14 and September 28 settlement dates, those sellers were looking for direction.

Trey Thoelcke
9:45am ET
Health and Healthcare

Why Geron Is Getting Crushed

Geron shares were absolutely crushed on Thursday morning after it was announced that Janssen Biotech has terminated the 2014 collaboration and license agreement with the firm.

Chris Lange
6:35am ET
Investing

The 6 Most Shorted Nasdaq Stocks

Judging by the most shorted stocks traded on the Nasdaq between the August 31 and September 14 settlement dates, those sellers were focused on Qualcomm.

Trey Thoelcke
6:40am ET
Investing

The 6 Most Shorted Nasdaq Stocks

Judging by the most shorted stocks traded on the Nasdaq between the August 15 and August 31 settlement dates, those sellers may have been looking for direction.

Trey Thoelcke
6:50am ET
Investing

The 6 Most Shorted Nasdaq Stocks

Judging by the most shorted stocks traded on the Nasdaq between the July 31 and August 15 settlement dates, those sellers were focused on one favorite -- Caesars Entertainment.

Trey Thoelcke
7:10am ET
Investing

The 5 Most Shorted Nasdaq Stocks

Judging by the most shorted stocks traded on the Nasdaq between the July 31 and August 15 settlement dates, those sellers were focused on one favorite -- Caesars Entertainment.

Trey Thoelcke
6:50am ET
Investing

The 6 Most Shorted Nasdaq Stocks

Judging by the most shorted stocks traded on the Nasdaq between the July 13 and July 31 settlement dates, those sellers were looking for direction, as moves in their favorites were mixed…

Trey Thoelcke
6:45am ET
Investing

The 6 Most Shorted Nasdaq Stocks

Judging by the most shorted stocks traded on the Nasdaq between the June 29 and July 13 settlement dates, those sellers were cautious, as their favorites saw shrinking or flat short interest.

Trey Thoelcke
6:45am ET
Investing

The 5 Most Shorted Nasdaq Stocks

Judging by the most shorted stocks traded on the Nasdaq between the June 15 and June 29 settlement dates, those sellers were focused on a few of favorites.

Trey Thoelcke

Frequently Asked Questions

What does Geron do?

Geron Corporation is a commercial-stage biopharmaceutical company focused on hematology and blood cancers, built on expertise in telomerase biology. Its sole marketed medicine is RYTELO (imetelstat), a first-in-class oligonucleotide telomerase inhibitor.

What is the GERN stock price target?

The Wall Street consensus 12-month price target for GERN is $3.50.